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Abstract
Hepatocellular carcinoma (HCC) remains one of the most common and lethal malignancies worldwide despite the
development of various therapeutic strategies. A better understanding of the mechanisms responsible for HCC
initiation and progression is essential for the development of more effective therapies. The cancer stem cell (CSC)
model has provided new insights into the development and progression of HCC. CSCs are specialized tumor cells
that are capable of self-renewal and have long-term repopulation potential. As they are important mediators of
tumor proliferation, invasion, metastasis, therapy resistance, and cancer relapse, the selective targeting of this crucial
population of cells has the potential to improve HCC patient outcomes and survival. In recent years, the role of
epithelial-to-mesenchymal transition (EMT) in the advancement of HCC has gained increasing attention. This
multi-step reprograming process resulting in a phenotype switch from an epithelial to a mesenchymal cellular state
has been closely associated with the acquisition of stem cell-like attributes in tumors. Moreover, CSC mediates
tumor metastasis by maintaining plasticity to transition between epithelial or mesenchymal states. Therefore,
understanding the molecular mechanisms of the reprograming switches that determine the progression through
EMT and generation of CSC is essential for developing clinically relevant drug targets. This review provides an
overview of the proposed roles of CSC in HCC and discusses recent results supporting the emerging role of EMT in
facilitating hepatic CSC plasticity. In particular, we discuss how these important new insights may facilitate rational
development of combining CSC- and EMT-targeted therapies in the future.
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Background
Hepatocellular carcinoma (HCC) is the most commonly
diagnosed malignancy of the liver and is the third most
frequent cause of cancer mortality worldwide [1–4]. HCCs
are highly aggressive carcinomas that are often fatal due
to high level of tumor invasiveness, intrahepatic spread,
and extrahepatic metastasis [5, 6]. HCCs are multifactorial
and its incidence is highly correlated to chronic inflamma-
tion and cirrhosis. Chronic hepatitis B and C infections
and alcohol overconsumption are considered to be risk
factors for HCC [7–9]. The prognosis for patients with ad-
vanced HCC remains extremely poor due to the high rates
of recurrence and metastasis. Conventional treatments for
HCC patients such as liver resection, transplantation, and
chemotherapy have shown limited efficiency in advanced
disease [10–12]. Thus, the ultimate goal in combating
HCC in advanced stages is to overcome therapeutic resist-
ance and to prevent disease recurrence.
The precise molecular mechanisms of HCC pathogen-
esis are unclear. HCC features significant genetic, pheno-
typic, and functional heterogeneity, with the potential to
confound the success of many therapies. A molecular
basis of heterogeneity in HCC was evidenced by studies
that found markedly different molecular profiles among
cells from clinical specimens [13–15]. HCC intratumoral
heterogeneity is a hallmark feature that represents a sub-
stantial obstacle to achieving favorable clinical response in
patients. Clonal evolution, cancer stem cell, and pheno-
type plasticity models have been postulated to explain
how tumor cell heterogeneity arises (Fig. 1). These models
are essentially used to describe cancer development, with
the differences between the models having important
implications for the rational design of drugs and treatment
strategies.
Clonal evolution or stochastic model suggests that serial
acquisition of mutations generates tumor cell heterogen-
eity and contributes to cancer progression. With each new
advantageous mutation, a clonal growth of novel cell pop-
ulations completely or partially overgrows the old [16, 17].
In accordance with this model, most cancer cells possess
the mutations and molecular changes that gave the cells
their malignant properties, and therefore, removing the
bulk of the tumor will curtail tumor progression. However,
the view that every cancer cell has the same or equal
potential to support disease progression has long been
challenged. In the early 1970s, it was recognized that not
all cancer cells are capable of extensive proliferation in
colony formation assays [18]. This has been expanded to
in vivo studies showing that not all cells within a cancer
are able to initiate tumors when implanted into mice [19].
The second model of cancer stem cell (CSC) or
cancer-initiating cell (CIC) theory supports the pres-
ence of a specific subpopulation of cancer cells that
possess tumorigenic potential and generates tumor
cell heterogeneity [20]. According to this model, the
identification of targeted therapies to remove the
CSCs would lead to tumor regression and disease
stabilization. This theory postulates the existence of a
unidirectional differentiation hierarchy, where non-
CSCs cannot generate CSCs. However, it is becoming
increasingly apparent that differentiated cells can be
switched to generate CSCs [21].
Phenotype plasticity model posits that irreversibly dif-
ferentiated cells can be converted back to an undifferen-
tiated state or stem cell-like state given the appropriate
stimulus [22, 23]. This model suggests that CSCs are a
dynamic subpopulation of cancer cells rather than a
stable cell population and has important implications for
the design of combination therapies. Several intriguing
studies have described that HCC cells hijack portions of
the developmental epithelial-to-mesenchymal transition
(EMT) program to generate CSCs, thereby facilitating
metastasis and drug resistance [24–26]. EMT process
provides a means to link clonal evolution and CSC
models and forms the basis for phenotypic plasticity
model [21]. Here, we summarize new insights into the
molecular mechanisms that link CSCs and EMT in
HCC. Deciphering the relationships between these fun-
damental processes will expand our knowledge of the
underlying etiology and pathogenesis of HCC and lead
to development of novel clinical targets and improve the
clinical management of HCC patients.
Cancer stem cells
According to the CSC hypothesis, tumors are organized
into a hierarchy of heterogeneous cell populations, and
only a small subset of cells within a tumor, termed CSCs
or CICs, have the ability to sustain tumor formation and
growth [27–29]. The CSC model has provided an
important conceptual framework that has proven highly
useful for understanding intratumoral heterogeneity
[30]. CSCs are similar to normal stem cells in their abil-
ity to perpetuate themselves through self-renewal and
generate large populations of more differentiated de-
scendants [27, 31]. The differentiation of CSCs results in
the recapitulation of the cellular heterogeneity of the ori-
ginal tumor. CSCs can seed tumors when transplanted
into immune-compromised animal host [19, 20, 32].
CSCs may also exhibit inherent drug resistance and
enhanced invasive and migratory potential that implicate
a role in disease pathogenesis spanning initial tumor for-
mation to metastatic disease progression [33]. The CSC
model also provides a framework for therapeutic failure
and relapse [34]. These hurdles can be overcome by
characterization of CSCs and the identification of spe-
cific targeted therapies to eliminate CSCs. Given that
CSCs exist in most hematological and solid tumors, they
have emerged as potential targets [28, 29, 35, 36]. CSCs
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have been identified and harvested using a number of
different strategies that have been extensively reviewed
elsewhere [37, 38].
Cancer stem cells and their implications in HCC
CSCs have proven to play a central role in the develop-
ment, maintenance, metastasis, and recurrence of HCC
[39–42]. Initially, CSC populations were identified and
isolated from human HCC cell lines and xenograft tumors
characterized by their expression of CD133, a cell surface
glycoprotein [43, 44]. CD133+ cancer cells exhibited stem
cell-like properties, including higher proliferative poten-
tial, greater colony-forming efficiency, self-renewal, and
differentiating capacity when compared to CD133– coun-
terparts. Additionally, CD133+ cells could initiate tumor
growth in vivo, suggesting validation of the CD133 marker
for enrichment of CSCs in HCC [43]. Besides CD133
expression, HCC cells possessing CSC attributes have
been reported to express diverse cell surface CSC markers
such as CD90, CD44, CD13, and epithelial cell adhesion
molecule (EpCAM) [39, 45–48]. Isolating CSCs on the
basis of single markers has, however, proven to be
not definitive, with cells derived from negative populations
often inducing tumors albeit at a reduced capacity. Hence,
utilizing a combination of different markers that co-express
would be a better strategy to isolate CSCs from HCC. For
instance, co-expression of surface markers including CD44,
CD90, and CD133 has been used to isolate CSCs in HCC
[49]. However, co-expression of CSC markers has shown
the existence of heterogeneity within the CSC populations
of even the same patient tumor samples [50]. A recent
study has demonstrated that heterogeneous CSC popula-
tions interact and influence functional traits within a single
tumor. Notably, upon co-culturing CD90+ and EpCAM+
CSC populations, CD90+ CSCs were able to promote mo-
tility in non-motile epithelial-like EpCAM+ CSCs [45].
Although a number of molecules have been identified as
markers for CSC, there is no general consensus on the
best CSC markers for HCC. Moreover, there is high vari-
ability in marker expression across established cell lines
and HCC tumors and their suitability for therapeutic
targeting has not been extensively evaluated [49, 51].
Hence, there is still a critical need for identification of
more robust markers for the enrichment of hepatic CSC.
Side population flow cytometry using Hoechst 33342
staining and sphere formation assays based on functional
aspects of CSCs have been utilized for enriching hepatic
CSCs [52, 53]. Tumorspheres possess the capacity for self-
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Fig. 1 Different models of tumor heterogeneity. a Clonal evolution or stochastic model suggests that serial acquisition of mutations generates
tumor cell heterogeneity and all cells are capable of renewal and tumorigenesis. b According to the cancer stem cell (CSC) model, tumors are
organized into a hierarchy of heterogeneous cell populations, and only a small subset of cells within a tumor called CSCs have the ability to sustain tumor
formation. CSCs have the ability to perpetuate themselves through self-renewal and generate large populations of more differentiated descendants by
unidirectional conversion. c Phenotype plasticity model posits that irreversibly differentiated cells can be converted back to an undifferentiated state or
stem cell-like state given the appropriate stimulus. This dynamic bidirectional conversion between CSC and non-CSC can give rise to tumor heterogeneity
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renewal and tumorigenicity and thus represent a more
precise tool for the enrichment of CSCs [54]. For a com-
prehensive review on methods to isolate CSCs in HCC,
see Chiba et al. [55].
EMT: an essential developmental process
reactivated during cancer progression
EMT is a complex molecular and cellular reprograming
process by which epithelial cells lose their differentiated
characteristics and acquire mesenchymal features, includ-
ing motility, invasiveness, ability to escape immune cells,
and a heightened resistance to apoptosis [56]. EMT is an
essential process for morphogenetic events in embryonic
development which enables immobile epithelial cells to
gain a motile mesenchymal phenotype [57, 58]. In cancers,
the inappropriate induction of this developmental process
can be disastrous as they endow differentiated sessile
epithelial cells with migratory and invasive traits thereby
initiating the first step of tumor metastasis cascade [57,
59]. In support of this idea, EMT has been documented at
the invasive fronts of several cancer types [60, 61]. Mesen-
chymal cells can undergo a reverse phenotype switching
to regain epithelial state via mesenchymal-to-epithelial
transition (MET) to colonize new sites and create second-
ary tumors in distant organs [62]. Thus, EMT is a dy-
namic and reversible process, which allows cancer cells to
reversibly transition between epithelial and mesenchymal
states during the metastasis process. Phenotypic switching
of cells influences the prognosis of cancer patients by pro-
moting multidrug resistance of tumors and recurrence
[62, 63]. The molecular events driving EMT have been
delineated and reviewed in detail by Lamouille et al. [64].
EMT phenotypic cells as a resource for hepatic
CSCs
Recently, EMT has emerged as an important regulator of
cancer cells exhibiting stem cell-like properties [65]. The
best established example of the generation of CSC from
their non-CSC progeny comes from recent studies relating
breast CSC and EMT [62, 66]. These studies demon-
strated that the induction of EMT in immortalized human
mammary epithelial cells lead to the expression of both
mesenchymal markers and CD44highCD24low cell surface
marker profile characteristic of breast CSCs. Notably,
these cell populations also acquired self-renewal proper-
ties and enhanced tumor-initiating ability [62, 66]. Similar
studies have revealed the co-expression of both EMT- and
CSC-associated genes at the invasive front of colorectal
cancer and in spindle tumor cells inside the blood vessels
of patients with metastasis [63, 67]. Furthermore, compel-
ling evidence for the EMT-CSC link was provided by stud-
ies demonstrating the induction of EMT in cancer cells
resulted in the expression of CSC markers [62, 66, 68].
These studies reinforced the possibility that CSC and
EMT are mechanistically correlated and may be key com-
ponents of cancer progression and metastasis.
Transcription factors Snail and Slug have been estab-
lished as crucial regulators of EMT during embryonic
development, organ fibrosis, and cancer progression, as
they are potent repressors of E-cadherin expression.
Overexpression of Slug but not Snail has been reported
in the HCC cell line, HepG2, to induce EMT and en-
hance CSC marker CD133 [69]. The EMT-CSC link may
also be exploited to enrich for CSCs. Mitra et al. identi-
fied the existence of Vimentin on the surface of liver
CSCs and utilized this in a separation technique to
enrich EMT-positive CSCs directly from primary tumor
cells [70]. Similarly, Li et al. enriched CSCs from human
HCC cell lines and human primary HCC tumors by the
sphere-forming assay. These cells exhibited high expres-
sion of CD90 and mesenchymal marker Vimentin [71].
The connection between EMT and CSC indicates that
the EMT process is doubly dangerous for the cancer
patient and may explain how CSCs maintain their
aggressiveness in the long period of time when invading
and migrating to surrounding tissues [65]. Notably, the
link between CSC and EMT markers has been explored
in HCC patient cohort. EMT and CSC marker expres-
sion examination in 27 HCC patients by immunohisto-
chemistry revealed downregulation of epithelial marker
E-cadherin in 63 % of patients and upregulation of mes-
enchymal marker N-cadherin in 81 % of patients. This
patient cohort also showed upregulation of CSC marker
CD13 in 78 % of patients [72]. Given that both EMT and
CSC phenotypes are crucial for tumor progression and
metastasis, an in-depth investigation of crosstalk of
CSCs with EMT has important implications for our un-
derstanding of HCC progression.
EMT: the driver of hepatic CSC plasticity
EMT may provide a means to integrate the canonical
CSC model with the clonal evolution model. Given that
EMT drives a dedifferentiation-like process whereby
non-CSCs can be reprogramed to gain a CSC phenotype,
it supports a bidirectional CSC model. Chaffer et al. pro-
posed that some tumors adhere to phenotypic plasticity
model wherein dynamic bidirectional conversions
between the CSC and non-CSC compartments are com-
mon and essential components of tumorigenicity. A
study on breast cancer suggests that aggressive CSCs
can be created de novo within a tumor by spontaneous
mechanisms that pertains to a switch in cell phenotype
and is not driven by additional genetic mutations [21].
Another study revealed that more differentiated breast
cancer cells can give rise to cells expressing breast CSC
markers and that the rate of interconversion is variable
between cells from different lesions [73]. CSCs might be
generated with processes that are related to activation of
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EMT, which impacts cell differentiation and tumor
metastatic potential [74]. Phenotypic plasticity would
provide an extremely robust system as most or all cells
could regenerate heterogeneity if a particular cell type
was removed, in contrast to the reliance on random
mutations implicit in clonal evolution.
Recent data suggests that CSCs are indeed plastic and
can be associated with both epithelial and mesenchymal
states. Occurrence of two distinct populations of CSCs
termed EMT-CSCs with epithelial signature and MET-
CSCs with mesenchymal signature have been reported
in breast cancer. These CSCs have the capacity to transi-
tion between these cellular states. It has been envisioned
that EMT-CSCs are located at the invasive edge of the
tumor and allow the tumor to expand into new territory.
On the other hand, MET-CSCs are located in the tumor
interior and facilitate tumor cell growth. Furthermore,
when the invasive edge becomes the interior of the
tumor, the two CSCs can change cellular states [75]. It is
conceivable that CSCs with distinct EMT/MET pheno-
types also occur in HCC. In support for this hypothesis,
CSCs with mesenchymal phenotypes were observed in
the invasive front of HCC patient samples [24, 76]. In
an earlier study of CSC populations defined by
CD133+/ALDHhigh and CD133+/EpCAM+ separated
from Huh7, HepG2, and Hep3B, well-differentiated
human HCC cell lines were deemed to be epithelial
by expression of E-cadherin and lack of Vimentin. In
contrast, poorly differentiated cell lines such as
SkHep1, HLE, and HLF and double negative subpopu-
lation from well-differentiated cell lines were charac-
terized as mesenchymal due to the higher expression
of Vimentin, Zeb1, and Snail; and transforming
growth factor (TGF)-β and hedgehog pathway activation
[77]. Another study examined microarray data from 238
HCC cases and found several distinct subpopulations char-
acterized by expression of CD133, CD90, and EpCAM.
Gene expression revealed an enriched EMT signature in
CD90+ cells. Further examination of both primary tumors
and HCC cell lines demonstrated that CD90+ subpopula-
tion of cells were mesenchymal and overexpressed CD44,
c-KIT, and TWIST1, whereas EPCAM+ subpopulation
were epithelial and expressed alpha-fetoprotein (AFP) and
Albumin [45]. The plasticity of these distinct subpopula-
tions to switch between different EMT cellular states
warrants further investigation.
EMT phenotype is linked with the biology of CSC
in HCC
Recent studies in HCC have demonstrated that the EMT
phenotype and CSC biology are intricately linked. Thus,
identifying common molecular pathways regulating CSC
and EMT attributes may be critical for the development
of efficacious treatment strategies for HCC patients.
Table 1 provides a list of cell surface molecules, tran-
scription factors, microenvironmental cues, and micro
RNAs (miRNAs) that have been implicated in the mo-
lecular pathways linking CSCs to EMT in HCC. Recent
studies provide evidence for the emergence of cells with
combined EMT and CSC phenotypes. For example, cell
surface marker Keratin19+ (K19+) expressing human
HCC cells exhibited CSC-like properties together with
Table 1 Determinants of CSC and EMT in HCC
Molecular regulator Signaling pathway Study
Cell surface markers
K19+ TGF-β-Smad Kawai et al. [24]
CD44+ ERK/Snail; Gao et al. [78]
TGF-β/Smad; Akt/
GSK-3β/β-catenin
Park et al. [79]
CD133+ NF-kB Liu et al. [26]
CD90+ Yamashita et al. [45]
EpCAM Yamashita et al. [45]
Vimentin+CD133- Mitra et al. [70]
Transcription factors
Nanog Stat3/Snail Yin et al. [25];
Yu et al. [80]
Oct4 Stat3/Snail Yin et al. [25]
Slug Sun et al. [69]
Sox9 TGF-β/Wnt/β-catenin Kawai et al. [82]
Oncogene
Malestrom Akt/GSK-3β/Snail Liu et al. [81]
Microenvironmental cues
Hepatic stellate cells HGF/Met Yu et al. [91]
Tumor-associated
macrophages
TGF-β1 Fan et al. [76]
Artemin Zhang et al. [83]
Hypoxia Akt Zhang et al. [83]
Twist1/Bmi1 Liu et al. [92]
HIF-1α/Artemin/Akt Zhang et al. [83]
Oxidative stress
HCV infection Ca2+ signaling Iqbal et al. [94]
Folate deficiency miR-22 Su et al. [95]
Viral infection
HCV geneotype 2A Hypoxia/osteopontin/Akt/
GSK-3β/β-catenin
Kwon et al. [84]
Iqbal et al. [94]
miRNA
miR-200a Wnt/β-catenin Liu et al. [87]
miR-125b TGF-β/SMAD2/4 Zhou et al. [72]
miR-148b Liu et al. [88]
miR-200b, miR-200c,
miR-122, miR-145
DDX3 Li et al. [89]
Sphere formation Notch Li et al. [71]
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elevated EMT marker expression. Activation of TGF-β
and Smad signaling axis in K19+ cells has been impli-
cated in mediating EMT [24]. Similarly, another study
revealed that CD44, a putative CSC marker, is associated
with a mesenchymal phenotype in HCC cell lines. CD44+
cells expressed high levels of mesenchymal markers
N-cadherin and Vimentin and low levels of epithelial
marker E-cadherin. Knockdown of CD44 reversed EMT
by repression of ERK/Snail pathway and inhibited lung
metastasis of HCC cells in the metastatic model of HCC
established by tail vein injection of luciferase-labeled HCC
cells in nude mice [78]. A recent study found that CD44
protein levels were enhanced by TGF-β1 treatment and
that synergistic interactions between CD44 and TGF-β1
induced EMT and CSC phenotypes through Akt/GSK-3β/
β-catenin signaling axis in HCC [79]. Another study dem-
onstrated that by targeting CSC marker CD133, CSC and
EMT traits can be abrogated [26]. These studies have
identified a clear functional link between EMT and CSC,
as altered expression of CSC cell surface markers can con-
versely affect the EMT process.
Pluripotency factors, oncogenes, and viral infection
that result in the generation of CSCs in HCC, also con-
fer these cells with EMT features. For instance, ectopic
expression of pluripotency associated transcription fac-
tors Oct4 and Nanog that are essential for maintenance
of stem cell phenotype endowed HCC cell line
MHCC97-L with both CSC and EMT traits through the
activation of signal transducer and activator of transcrip-
tion 3 (Stat3)/Snail signaling [25]. Furthermore, Yu et al.
demonstrated that disruption of Nanog expression
resulted in downregulation of pluripotency factors Oct4,
Klf4, and Sox2; and CSC marker CD133 and reversal of
EMT [80]. Another study examined the effect of onco-
gene Maelstrom that is generally silenced at a transcrip-
tional level in somatic tissues, on the acquisition of CSC
and EMT features in HCC cells. Liu et al. demonstrated
that Maelstrom upregulated stemness-associated genes
(Nanog, Oct4, Bmi-1, Notch-1, and Smo), CSC markers
(CD24, CD44, CD133, CD105, and CD166) and EMT
markers (Snail, Slug, Vimentin, and Fibronectin). They
also demonstrated that Maelstrom ectopic expression in
HCC cells is associated with the acquisition of EMT and
CSC features through the activation of AKT/GSK-3β/
Snail axis [81]. Similarly, sex-determining region Y-box 9
(SOX9), a transcription factor expressed in embryonic
liver but not in adult hepatocytes, has been found to in-
duce EMT and CSC traits via the activation of TGF-β/
Smad and Wnt/β-catenin signaling pathways [82].
Similarly, Artemin, an estrogen-regulated growth fac-
tor which promotes resistance to antiestrogen therapies,
has been shown to modulate EMT features of HCC cells
with downregulation of E-cadherin and upregulation of
N-cadherin, Vimentin, Snail, and E47. Artemin promotes
the metastatic properties and tumor-initiating capacity
of HCC by AKT modulation of factors involved in EMT
and stemness [83]. Chronic hepatitis C virus (HCV)
infection, an important factor in the etiology of HCC, is
also associated with EMT and CSC pathways. Human
primary hepatocytes infected with cell culture grown
HCV genotype 2a revealed enhanced EMT markers
(Snail, Slug, Twist, and Vimentin) and stemness markers
(CD133, Nanog, Lin28A, Oct4A, Notch-1, c-Myc, and
c-Kit) [84].
Recent studies of non-coding RNAs are shedding light
on the regulation of EMT and CSC in cancers [85, 86].
Studies focused on hepatic oval cells as the source of
hepatic CSCs have uncovered miR-200a as a suppressor of
EMT and CSC signatures. Stable knockdown of miR-200a
conferred mesenchymal and CSC characteristics to rat
hepatic oval cell line WB-F344 via activation of Wnt/β-ca-
tenin pathway [87]. Additionally, in a cell culture model
where HCC cell lines were treated with 10 ng/ml TGF-β1
for 4 to 6 days, miR-125b was found to be downregulated.
miR-125b blocked EMT and exerted its inhibitory effects
via SMAD2 and 4 [72]. Another study revealed that miR-
148b was downregulated in HCC side populations (SP)
that were selected based on efflux of Hoechts 33342 dye.
SP cells of HCC were enriched for CSC-like properties.
Functional studies demonstrated that miR-148b abrogated
the expression of CSC and EMT markers [88]. Recently,
reduced expression of DDX3, a member of the DEAD-box
RNA helicase family, has been correlated with poor HCC
patient survival and conferred HCC cells with CSC and
EMT traits. Moreover, DDX3 expression positively
correlated with transcription of several tumor-suppressive
miRNAs, namely, miR-200b, miR-200c, miR-122, and
miR-145 [89].
In addition to intracellular factors influencing EMT
and CSCs, recent studies have found that interaction
among cancer cells and stromal cells within the tumor
microenvironment can induce EMT by secretion of
mediators such as growth factors, cytokines, and extra-
cellular matrix proteins [90]. Accordingly, reciprocal sig-
naling between hepatic stellate cells and precancerous
hepatoma cells induced an EMT and CSC-like properties
in HCC mediated by hepatocyte growth factor (HGF)/
Met signaling [91]. Similarly, exposure to conditioned
media from tumor infiltrating macrophages (TAMs) rich
in TGF-β1 promoted hepatoma cells to undergo EMT
and to gain CSC-like properties [76]. These studies
reinforce the involvement of tumor stroma in mediating
EMT and generating CSC in HCC.
Rapid growth of cancer cells often creates insufficient
supply of oxygen and results in hypoxic microenvironment.
A hypoxic microenvironment is a common feature of HCC
and is associated with malignant invasion, metastasis,
EMT, and CSC [92, 93]. A previous study has established
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that hypoxia upregulated the expression of Twist1 and
Bmi1, two proteins that have important roles in inducing
EMT and cancer cell stemness [92]. Another study has
demonstrated that HCV infection of human HCC cells
induced osteopontin that triggered an EMT process via the
Akt/GSK-3β/β-catenin axis [94]. Furthermore, this study
demonstrated that osteopontin induces downstream sig-
naling cascade via the receptor CD44, a marker of CSC in
HCC. Moreover, a concomitant elevation of ROS in the
mitochondria of HCV infected HCC cells as a result of en-
hanced Ca2+ signaling has implicated the importance of
oxidative stress in promoting EMT and CSC in HCC [94].
A recent study demonstrated that HCC cells cultured
under folate deficiency culture condition elicited a signifi-
cant increase in intracellular reactive oxygen species, ac-
companied by activation of EMT and CSC phenotypes.
Mechanistically, this study showed decreased miR-22 level
leads to EMT and CSC traits under folate deficiency [95].
These studies have suggested oxidative stress as a key fac-
tor in promoting metastasis. However, detailed mechanistic
explanations linking oxidative stress to CSC and EMT in
HCC remains to be elucidated.
The transcription factor hypoxia-inducible factor-1α
(HIF-1α), a key mediator of the cellular response to
hypoxia, is overexpressed in HCC [96]. A recent study
suggested that during hypoxia, HIF-1α upregulated
Artemin expression and this in turn promoted CSC and
EMT functions in HCC [83]. Won et al. demonstrated
that hypoxia could trigger Stat3-mediated CD133 upreg-
ulation with concomitant enhanced HIF-1α levels [96].
Interestingly, another study demonstrated that Frizzled2
(FZD2) activated Stat3 signaling induced EMT in HCC
[97]. More studies are needed to better understand the
contribution of hypoxia and Stat3 in mediating EMT
and CSC in HCC. Collectively, these studies suggest a
relationship between tumor hypoxia, EMT, and CSC.
However, the molecular mechanisms that relay the hyp-
oxia signal into hepatic EMT and CSC are still largely
elusive and warrant further investigation.
EMT- and CSC-associated resistance to cancer
therapeutics
Recent evidences indicate that HCC patients manifesting
both CSC and EMT phenotypes are unresponsive to
standard chemotherapies and have low progression free
survival [24]. This may be explained by the persistence
of CSCs, partly generated and maintained by EMT.
CSCs are inherently resistant to drugs and toxins
through high expression of several ATP-binding cassette
(ABC) transporters, an increased DNA repair capacity,
and resistance to apoptosis [20, 98]. HCC cells double-
positive for CSC and EMT markers were more resistant
to chemotherapeutic agents such as cisplatin, doxorubi-
cin, paclitaxel, and sorafenib due to elevated expression
of ABC superfamily transporters ABCC2, ABCG2, and
MDR1 [25, 81, 87]. Others demonstrated that K19+
HCC cells were resistant to 5-Fluorouracil treatment by
high expression of a drug transporter, multidrug resist-
ance protein 5 (MRP5) [24]. Sorafenib, an orally-
available kinase inhibitor, is the only standard clinical
treatment against advanced HCC. Increasing evidence
suggests that sorafenib resistance in HCC is correlated
with the activation of EMT and enrichment of CSC traits
[99–101]. Furthermore, EMT and CSC have been impli-
cated as key mechanisms leading to tumor recurrence in
patients who received radiofrequency ablation (RFA)
treatment for local control of HCC [102]. Identifying the
mechanisms by which EMT-transformed CSCs initiate
relapse could facilitate the development of new or
enhanced personalized therapeutic regimens.
Therapies targeting CSC and EMT phenotypes
The association of EMT and CSCs may also form the
basis for identifying novel targeting agents to improve
clinical outcomes in HCC patients (Fig. 2). One potential
approach is using monoclonal antibodies to target the
CSC cell surface antigens that regulate EMT. For
example, the use of specific monoclonal antibodies
against CD44 or CD133 may prove to be effective in
completely eliminating HCC cells with CSCs and EMT
phenotypes. As evidence for this, recent studies have
demonstrated that shRNA mediated CD44 or CD133
knockdown reversed the EMT phenotype [26, 78]. An-
other approach is to perform high-throughput chemical
screen to identify compounds that could induce cell
death in CSCs generated by EMT. The ionophore salino-
mycin was identified as a potential CSC targeting agent
that subsequently blocked tumor formation and metas-
tasis in vivo in different malignancies [103, 104]. Recent
studies have revealed that salinomycin was found to
exert synergistic cytotoxicity in combination with
chemotherapy drugs such as doxorubicin and fluoroura-
cil (5-FU) in HCC cells. These combination treatments
were able to target both CSC and EMT phenotypes [105,
106]. Furthermore, salinomycin-loaded poly(lactic-co-
glycolic acid) nanoparticles conjugated with both CD133
and epidermal growth factor receptor (EGFR) aptamers
could effectively target HCC cells simultaneously
expressing EMT mediator EGFR and CD133 [107]. The
activation of EGFR is known to elicit an EMT in HCC
[108]. Given the success of salinomycin in pre-clinical
studies in HCC, it can be envisaged that it will be the
object of future clinical studies. Treatment of HCC cell
lines with Songyou Yin (SYY, a traditional Chinese medi-
cine containing five herbal compounds) reduced CSC
markers (CD90, CD133, CD44, CD24, and EpCAM) and
mesenchymal marker Vimentin and restored epithelial
marker E-cadherin. Furthermore, combination treatment
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of SYY and Oxaliplatin in nude mice bearing orthotopic
xenografts reduced both CSC and EMT phenotypes
[109, 110]. Pterostilbene, a compound isolated from red
sandalwood and blueberry reduced CD133 subpopula-
tion of human HCC cell line Mahlavu. Pterostilbene
treatment also reversed EMT in these cells by increasing
the expression of E-cadherin and suppressing the ex-
pression of mesenchymal markers Vimentin and Twist 1
[111]. Recently, treatment with Sophocarpine, a com-
pound derived from the foxtail-like sophoraherb yielded
fewer CSCs in HCC cell lines HCC-LM3 and MHCC-
97H. Sophocarpine treatment reduced stem cell markers
and inhibited TGF-β-induced EMT [112].
As EMT signaling is involved in development and
maintenance of hepatic CSCs, an improved understand-
ing of EMT signaling networks and identifying key
molecular players linking these cellular phenotypes may
uncover new therapeutic targets. For instance, HGF/
MET signaling axis is a potential target as HGF neutral-
izing antibody effectively reduced activation of HGF/
MET signaling and concurrently blocked promotion of
EMT and CSC phenotypes and cisplatin resistance [91].
Inhibition of TGF-β1 pathway with a neutralizing anti-
body or a TGF-β receptor 1 inhibitor has shown to block
EMT and CSC traits in HCC cell line [24, 76]. Interest-
ingly, dual inhibition of CD44 and TGF-β1 exerted an
anti-metastatic effect with reduced migration and sphere
formation more strongly than inhibition of either one
alone [79]. Targeting Stat3 signaling pathway may repre-
sent another potential approach to overcome EMT
process in HCC displaying stemness and EMT [25].
Signaling networks mediated by microRNAs and
EMT-inducing transcription factors tie the EMT process
to regulatory networks that maintain stemness can serve
as possible targets. For instance, overexpression of miR-
125b has been effective in targeting EMT and CSC in
HCC by regulating transcription factor SMADs 2 and 4
[72]. Although some miRNAs have been identified to
regulate EMT in liver cancer, the role of miRNAs in the
EMT and CSC of HCC deserve further investigation
[106, 113].
Immunotherapeutic approaches comprise an alterna-
tive attractive therapy option, although current studies
in targeting CSC and EMT in HCC with immunotherapy
are somewhat limited. A recent study showed that EMT
signature from multiple cancer types was associated with
enrichment of multiple druggable immune targets [114].
Notably, the introduction in clinical practice of agents
that target the blockade of immune checkpoints has im-
proved the survival of patients with solid tumors [115,
116]. It would be of interest to examine whether these
immune checkpoints are regulated in CSC and EMT
phenotypes. For instance, the tumor-restricted pattern of
expression of the transcription factor Brachyury and its
CSC-and EMT-targeted 
therapies
Complete elimination 
of HCC tumors
Monoclonal Antibodies Small molecular pathway inhibitors and 
compounds
miRNA Immunotherapy
CSC-targeted
therapies
Elimination of CSCs
and 
tumor regression
EMT
Tumor relapse
loop CSC fo noisnapxEromut CCH suoenegoreteH
Heterogeneous HCC tumor
a
b
Generation 
of  CSCs
CD44
CD133
Keratin 19
HGF
TGF- 1
Stat3
Salinomycin
EGFR aptamers
SYY
Pterostilbene
Saphocarpine
miR-22
miR-200a
miR-200b
miR-200c
miR-122
miR-125b
miR-148b
CSC Cancer cells responsive to 
Undergo EMT
Non-CSCs
Differentiated cancer cells
TGF- 1
Anti-PD-L1
Brachyuryvaccine
Fig. 2 Possible targeted therapies for the treatment of HCC. a HCC tumor treatment modalities with CSC mediated treatment initially result in
tumor shrinkage and regression due to the elimination of CSCs. Some residual non-CSCs undergo EMT leading to repopulation of CSCs,
subsequently resulting in treatment failure and metastasis. b CSC and EMT therapies comprising of treatments targeting CSC and EMT
phenotypes with monoclonal antibodies, pathway inhibitors, miRNAs, or immunotherapy potentially leads to improved outcomes
Jayachandran et al. Journal of Hematology & Oncology  (2016) 9:74 Page 8 of 12
proven immunogenicity made it an appealing protein for a
cancer vaccine strategy targeting EMT [117]. The combin-
ation of these therapies with other interventions, such as
chemotherapy, radiotherapy, and targeted therapies opens a
window of opportunity for the cure of HCC. Thus, next-
generation therapies based on increased knowledge of CSC
and EMT characteristics and possibly, on the combination
of therapeutic interventions, such as immunotherapy and
CSC- and EMT-specific-targeted therapies, need to be
developed to achieve complete eradications of HCC
tumors.
Conclusions
The notion that CSC and EMT phenotypes play important
roles in HCC progression, metastatic competence, therapy
resistance, and relapse is a rapidly evolving concept that is
contributing to our understanding of HCC pathogenesis
and development of effective treatment options for this
cancer. Emerging research data indicate that the existence
of EMT and CSCs may be related to a high risk for recur-
rence and poor prognosis for many tumor types. Further
investigations into CSC and EMT biology will require add-
itional technological advances for the visualization, isola-
tion, and better characterization of HCC CSCs and EMT
phenotype, with robust biomarkers, and elucidation of the
signaling pathways that are altered in these tumor cells. Im-
proving our understanding of these cellular states may help
to categorize potential targets for novel therapies to pre-
clude relapse. Further research, especially characterization
of EMT and CSC phenotypes in HCC is needed for more
conclusive information.
As the molecular circuitries underlying EMT and
stemness appear closely intertwined, it will be vital to
further delineate key molecular players that link these
two cellular states. Recent data suggests that CSCs are
very plastic and can be associated with both epithelial
and mesenchymal states. This plasticity of CSCs further
suggests that targeting either state alone may not be suf-
ficient since the CSCs in the alternative state can rapidly
regenerate targeted cell populations. Hence, future in-
vestigations will be needed to simultaneously target
CSCs existing in both epithelial and mesenchymal states
to achieve complete tumor eradication. It remains to be
seen where combination of conventional chemotherapy
with agents that target CSC and EMT states may funda-
mentally enhance anticancer treatment in HCC.
Acknowledgements
Not applicable.
Funding
This work was supported by the Gallipoli Medical Research Foundation,
Australia.
Availability of data and materials
Not applicable.
Authors’ contributions
AJ, BD, and JCS contributed to the conception and design of the study. AJ,
BD, and JCS wrote, reviewed, and approved the submission of the study. All
authors read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 23 June 2016 Accepted: 24 August 2016
References
1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for
27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.
2. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal
A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al. Annual report to the
nation on the status of cancer, 1975-2006, featuring colorectal cancer trends
and impact of interventions (risk factors, screening, and treatment) to
reduce future rates. Cancer. 2010;116:544–73.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer.
2015;136:E359–386.
5. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and
management of postoperative recurrence after resection of hepatocellular
carcinoma. Ann Surg. 2000;232:10–24.
6. Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to
mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016.
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
8. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and
HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.
9. Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic
deconstruction of the cellular origin in liver cancer. Nat Rev Cancer.
2015;15:653–67.
10. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular
carcinoma. Oncogene. 2006;25:3866–84.
11. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent
advances. Hepatobiliary Pancreat Dis Int. 2008;7:237–57.
12. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet.
2012;379:1245–55.
13. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A,
Roberts LR, Demetris AJ, Sun Z, et al. A novel prognostic subtype of human
hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med.
2006;12:410–6.
14. Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, Moch H,
Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular
carcinoma. Clin Cancer Res. 2015;21:1951–61.
15. Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P, Chen K, Dong L, Cao L, Tao Y, et al.
Extremely high genetic diversity in a single tumor points to prevalence of non-
Darwinian cell evolution. Proc Natl Acad Sci U S A. 2015;112:E6496–6505.
16. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–8.
17. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet.
1993;9:138–41.
18. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a
primary cell culture assay. J Natl Cancer Inst. 1971;46:411–22.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF.
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad
Sci U S A. 2003;100:3983–8.
20. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer
stem cells. Nature. 2001;414:105–11.
21. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO,
Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem
Jayachandran et al. Journal of Hematology & Oncology  (2016) 9:74 Page 9 of 12
cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S
A. 2011;108:7950–5.
22. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in
cancer. Clin Chem. 2013;59:168–79.
23. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the
niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225–38.
24. Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda
K, Fukumitsu K, Mizumoto M, et al. Keratin 19, a cancer stem cell marker in
human hepatocellular carcinoma. Clin Cancer Res. 2015;21:3081–91.
25. Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ, Wu WZ, Ren ZG. Coexpression
of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular
carcinoma and promotes epithelial-mesenchymal transition through
activation of Stat3/Snail signaling. J Hematol Oncol. 2015;8:23.
26. Liu YM, Li XF, Liu H, Wu XL. Ultrasound-targeted microbubble destruction-
mediated downregulation of CD133 inhibits epithelial-mesenchymal
transition, stemness and migratory ability of liver cancer stem cells. Oncol
Rep. 2015;34:2977–86.
27. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med.
2006;355:1253–61.
28. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med.
1997;3:730–7.
29. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden
M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid
leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.
30. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer:
cancer stem cells versus clonal evolution. Cell. 2009;138:822–9.
31. Morrison BJ, Morris JC, Steel JC. Lung cancer-initiating cells: a novel target
for cancer therapy. Target Oncol. 2013;8:159–72.
32. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature.
2007;445:106–10.
33. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat
Med. 2009;15:1010–2.
34. Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B,
Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in
translational oncology: can we translate into clinical application? J Hematol
Oncol. 2015;8:16.
35. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S,
Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic
breast cancer cells with stem/progenitor cell properties. Cancer Res.
2005;65:5506–11.
36. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley
D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in
normal lung and lung cancer. Cell. 2005;121:823–35.
37. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J,
Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status
and future directions: AACR Workshop on cancer stem cells. Cancer Res.
2006;66:9339–44.
38. Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, Ping YF, Zhang X, Bian XW, Yu SC.
Strategies for isolating and enriching cancer stem cells: well begun is half
done. Stem Cells Dev. 2013;22:2221–39.
39. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT,
Fan ST. Significance of CD90+ cancer stem cells in human liver cancer.
Cancer Cell. 2008;13:153–66.
40. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells
confer chemoresistance by preferential expression of the Akt/PKB survival
pathway. Oncogene. 2008;27:1749–58.
41. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and
clinical significance of the stem cell marker CD133 in hepatocellular
carcinoma. Int J Clin Pract. 2008;62:1212–8.
42. Yan M, Li H, Zhu M, Zhao F, Zhang L, Chen T, Jiang G, Xie H, Cui Y, Yao M,
Li J. G protein-coupled receptor 87 (GPR87) promotes the growth and
metastasis of CD133+ cancer stem-like cells in hepatocellular carcinoma.
PLoS One. 2013;8:e61056.
43. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al.
CD133 positive hepatocellular carcinoma cells possess high capacity for
tumorigenicity. Int J Cancer. 2007;120:1444–50.
44. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY.
Identification and characterization of tumorigenic liver cancer stem/
progenitor cells. Gastroenterology. 2007;132:2542–56.
45. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS,
Hayashi T, Kondo M, Takatori H, et al. Discrete nature of EpCAM+ and
CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology.
2013;57:1484–97.
46. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H,
Takiuchi D, Hatano H, Nagano H, et al. CD13 is a therapeutic target in
human liver cancer stem cells. J Clin Invest. 2010;120:3326–39.
47. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in
hepatocellular carcinoma. J Hepatol. 2010;52:280–1.
48. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin
LX, Wauthier E, et al. EpCAM-positive hepatocellular carcinoma cells are
tumor-initiating cells with stem/progenitor cell features. Gastroenterology.
2009;136:1012–24.
49. Liu LL, Fu D, Ma Y, Shen XZ. The power and the promise of liver cancer
stem cell markers. Stem Cells Dev. 2011;20:2023–30.
50. Thakolwiboon S, Zhu J, Liang Q, Welling TH, Zhang M, Lubman DM.
Heterogeneity of the CD90(+) population in different stages of
hepatocarcinogenesis. J Proteomics Bioinform. 2014;7:296–302.
51. Wilson GS, Hu Z, Duan W, Tian A, Wang XM, McLeod D, Lam V, George J,
Qiao L. Efficacy of using cancer stem cell markers in isolating and
characterizing liver cancer stem cells. Stem Cells Dev. 2013;22:2655–64.
52. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka
O, Taniguchi H, Nakauchi H, Iwama A. The polycomb gene product BMI1
contributes to the maintenance of tumor-initiating side population cells in
hepatocellular carcinoma. Cancer Res. 2008;68:7742–9.
53. Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S, Oka M.
Cancer stem-like sphere cells induced from de-differentiated hepatocellular
carcinoma-derived cell lines possess the resistance to anti-cancer drugs.
BMC Cancer. 2014;14:722.
54. Morrison BJ, Steel JC, Morris JC. Sphere culture of murine lung cancer cell
lines are enriched with cancer initiating cells. PLoS One. 2012;7:e49752.
55. Chiba T, Iwama A, Yokosuka O. Cancer stem cells in hepatocellular
carcinoma: therapeutic implications based on stem cell biology. Hepatol
Res. 2016;46:50–7.
56. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nat Rev Cancer.
2009;9:265–73.
57. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer
cells. Science. 2013;342:1234850.
58. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J
Clin Invest. 2009;119:1420–8.
59. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal
transitions in development and disease. Cell. 2009;139:871–90.
60. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A,
Kirchner T, Brabletz T. A transient, EMT-linked loss of basement membranes
indicates metastasis and poor survival in colorectal cancer.
Gastroenterology. 2006;131:830–40.
61. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50:151–62.
62. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation
of breast cancer stem cells through epithelial-mesenchymal transition. PLoS
One. 2008;3:e2888.
63. Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, Brabletz T.
Epithelial-mesenchymal and mesenchymal-epithelial transitions during
cancer progression. Verh Dtsch Ges Pathol. 2007;91:21–8.
64. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
65. Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal
transitions in cancer and normal stem cells? Int J Cancer. 2011;129:2310–4.
66. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal
transition generates cells with properties of stem cells. Cell. 2008;133:704–15.
67. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell
and epithelial-mesenchymal transition markers are frequently overexpressed
in circulating tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 2009;11:R46.
68. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R, Badve S, Srour
EF, Nakshatri H. SLUG/SNAI2 and tumor necrosis factor generate breast cells
with CD44+/CD24- phenotype. BMC Cancer. 2010;10:411.
69. Sun Y, Song GD, Sun N, Chen JQ, Yang SS. Slug overexpression induces
stemness and promotes hepatocellular carcinoma cell invasion and
metastasis. Oncol Lett. 2014;7:1936–40.
Jayachandran et al. Journal of Hematology & Oncology  (2016) 9:74 Page 10 of 12
70. Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: a mislocalized
protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular
carcinoma cells expressing EMT markers. Int J Cancer. 2015;137:491–6.
71. Li J, Yu Y, Wang J, Yan Z, Liu H, Wang Y, Ding M, Cui L, Wu M, Jiang X, Qian
Q. Establishment of a novel system for the culture and expansion of hepatic
stem-like cancer cells. Cancer Lett. 2015;360:177–86.
72. Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, Jia
YL, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and
targets stem-like liver cancer cells through small mothers against
decapentaplegic 2 and 4. Hepatology. 2015;62:801–15.
73. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander
ES. Stochastic state transitions give rise to phenotypic equilibrium in
populations of cancer cells. Cell. 2011;146:633–44.
74. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and
cancer stem cells: a coalition against cancer therapies. J Mammary Gland
Biol Neoplasia. 2009;14:29–43.
75. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L,
McDermott SP, Landis MD, et al. Breast cancer stem cells transition between
epithelial and mesenchymal states reflective of their normal counterparts.
Stem Cell Reports. 2014;2:78–91.
76. Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH, Wei
LX. Tumor-associated macrophages promote cancer stem cell-like properties
via transforming growth factor-beta1-induced epithelial-mesenchymal
transition in hepatocellular carcinoma. Cancer Lett. 2014;352:160–8.
77. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial
mesenchymal transition and hedgehog signaling activation are associated
with chemoresistance and invasion of hepatoma subpopulations. J Hepatol.
2011;55:838–45.
78. Gao Y, Ruan B, Liu W, Wang J, Yang X, Zhang Z, Li X, Duan J, Zhang F, Ding
R, et al. Knockdown of CD44 inhibits the invasion and metastasis of
hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-
mesenchymal transition. Oncotarget. 2015;6:7828–37.
79. Park NR, Cha JH, Jang JW, Bae SH, Jang B, Kim JH, Hur W, Choi JY, Yoon SK.
Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-
catenin signaling during epithelial-mesenchymal transition in liver cancer
cells. Biochem Biophys Res Commun. 2016;477:568–74.
80. Yu AQ, Ding Y, Li CL, Yang Y, Yan SR, Li DS. TALEN-induced disruption of
Nanog expression results in reduced proliferation, invasiveness and
migration, increased chemosensitivity and reversal of EMT in HepG2 cells.
Oncol Rep. 2016;35:1657–63.
81. Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen L, Zhu YH, Li J, Ma S, Xie D, et al.
Maelstrom promotes hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling.
Hepatology. 2014;59:531–43.
82. Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H,
Yoshitoshi EY, Ogiso S, Kita S, et al. SOX9 is a novel cancer stem cell marker
surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep.
2016;6:30489.
83. Zhang M, Zhang W, Wu Z, Liu S, Sun L, Zhong Y, Zhang X, Kong X, Qian P,
Zhang H, et al. Artemin is hypoxia responsive and promotes oncogenicity
and increased tumor initiating capacity in hepatocellular carcinoma.
Oncotarget. 2016;7:3267–82.
84. Kwon YC, Bose SK, Steele R, Meyer K, Di Bisceglie AM, Ray RB, Ray R.
Promotion of cancer stem-like cell properties in hepatitis C virus-infected
hepatocytes. J Virol. 2015;89:11549–56.
85. Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang
W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and
mesenchymal-to-epithelial transitions. J Hematol Oncol. 2014;7:19.
86. Hao J, Zhang Y, Deng M, Ye R, Zhao S, Wang Y, Li J, Zhao Z. MicroRNA
control of epithelial-mesenchymal transition in cancer stem cells. Int J
Cancer. 2014;135:1019–27.
87. Liu J, Ruan B, You N, Huang Q, Liu W, Dang Z, Xu W, Zhou T, Ji R, Cao Y, et
al. Downregulation of miR-200a induces EMT phenotypes and CSC-like
signatures through targeting the β-catenin pathway in hepatic oval cells.
PLoS One. 2013;8:e79409.
88. Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T, Wang Z, Ying M, Zheng Q.
miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1.
Biosci Rep. 2015;35:4.
89. Li HK, Mai RT, Huang HD, Chou CH, Chang YA, Chang YW, You LR, Chen
CM, Lee YH. DDX3 represses stemness by epigenetically modulating tumor-
suppressive miRNAs in hepatocellular carcinoma. Sci Rep. 2016;6:28637.
90. Moustakas A, Heldin CH. Signaling networks guiding epithelial-
mesenchymal transitions during embryogenesis and cancer progression.
Cancer Sci. 2007;98:1512–20.
91. Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, Yang Y, Zhao Q, Li R, Wu M, Wei L.
Hepatic stellate cells secreted hepatocyte growth factor contributes to the
chemoresistance of hepatocellular carcinoma. PLoS One. 2013;8:e73312.
92. Liu K, Sun B, Zhao X, Wang X, Li Y, Qiu Z, Liu T, Gu Q, Dong X, Zhang Y, et al.
Hypoxia promotes vasculogenic mimicry formation by the Twist1-Bmi1
connection in hepatocellular carcinoma. Int J Mol Med. 2015;36:783–91.
93. Liu L, Ren ZG, Shen Y, Zhu XD, Zhang W, Xiong W, Qin Y, Tang ZY.
Influence of hepatic artery occlusion on tumor growth and metastatic
potential in a human orthotopic hepatoma nude mouse model: relevance
of epithelial-mesenchymal transition. Cancer Sci. 2010;101:120–8.
94. Iqbal J, McRae S, Banaudha K, Mai T, Waris G. Mechanism of hepatitis C virus
(HCV)-induced osteopontin and its role in epithelial to mesenchymal
transition of hepatocytes. J Biol Chem. 2013;288:36994–7009.
95. Su YH, Huang WC, Huang TH, Huang YJ, Sue YK, Huynh TT, Hsiao M, Liu TZ,
Th Wu A, Lin CM. Folate deficient tumor microenvironment promotes
epithelial-to-mesenchymal transition and cancer stem-like phenotypes.
Oncotarget. 2016.
96. Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, Lee JH, Jang JJ, Yoon JH,
Jeong WI, et al. Signal transducer and activator of transcription 3-mediated
CD133 up-regulation contributes to promotion of hepatocellular carcinoma.
Hepatology. 2015;62:1160–73.
97. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A
noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition
and metastasis. Cell. 2014;159:844–56.
98. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev
Cancer. 2005;5:275–84.
99. Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang
X, et al. Potential molecular, cellular and microenvironmental mechanism of
sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367:1–11.
100. Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT,
Pang RW. The enhanced metastatic potential of hepatocellular carcinoma
(HCC) cells with sorafenib resistance. PLoS One. 2013;8:e78675.
101. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu
HX, Kong LQ, Wu WZ, et al. Sorafenib down-regulates expression of HTATIP2
to promote invasiveness and metastasis of orthotopic hepatocellular
carcinoma tumors in mice. Gastroenterology. 2012;143:1641–9. e1645.
102. Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent
hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2016.
103. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES.
Identification of selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 2009;138:645–59.
104. Schenk M, Aykut B, Teske C, Giese NA, Weitz J, Welsch T. Salinomycin
inhibits growth of pancreatic cancer and cancer cell migration by
disruption of actin stress fiber integrity. Cancer Lett. 2015;358:161–9.
105. Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X, Liang T. Salinomycin
decreases doxorubicin resistance in hepatocellular carcinoma cells by
inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Oncotarget. 2015;6:10350–65.
106. Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J,
Zheng Y, et al. The synergistic in vitro and in vivo antitumor effect of
combination therapy with salinomycin and 5-fluorouracil against
hepatocellular carcinoma. PLoS One. 2014;9:e97414.
107. Jiang J, Chen H, Yu C, Zhang Y, Chen M, Tian S, Sun C. The promotion of
salinomycin delivery to hepatocellular carcinoma cells through EGFR and
CD133 aptamers conjugation by PLGA nanoparticles. Nanomedicine (Lond).
2015;10:1863–79.
108. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate
sensitivity to epidermal growth factor receptor inhibition in human
hepatoma cells. Cancer Res. 2008;68:2391–9.
109. Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, Liang L, Jiang XM, Tang ZY.
Herbal compound “Songyou Yin” renders hepatocellular carcinoma sensitive
to Oxaliplatin through inhibition of stemness. Evid Based Complement
Alternat Med. 2012;2012:908601.
110. Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD,
Liu L, et al. Residual hepatocellular carcinoma after oxaliplatin treatment has
increased metastatic potential in a nude mouse model and is attenuated by
Songyou Yin. BMC Cancer. 2010;10:219.
Jayachandran et al. Journal of Hematology & Oncology  (2016) 9:74 Page 11 of 12
111. Lee CM, Su YH, Huynh TT, Lee WH, Chiou JF, Lin YK, Hsiao M, Wu CH, Lin
YF, Wu AT, Yeh CT. BlueBerry isolate, Pterostilbene, functions as a potential
anticancer stem cell agent in suppressing irradiation-mediated enrichment
of hepatoma stem cells. Evid Based Complement Alternat Med.
2013;2013:258425.
112. Zhang PP, Wang PQ, Qiao CP, Zhang Q, Zhang JP, Chen F, Zhang X, Xie WF,
Yuan ZL, Li ZS, Chen YX. Differentiation therapy of hepatocellular carcinoma
by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced
EMT with sophocarpine. Cancer Lett. 2016;376:95–103.
113. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal
transition targets PTEN and SMAD7 to promote drug resistance and
recurrence of liver cancer. Hepatology. 2013;58:629–41.
114. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F,
Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, pan-cancer
EMT signature identifies global molecular alterations and immune target
enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res.
2016;22:609–20.
115. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A,
Robert C, Gangadhar TC, et al. Evaluation of immune-related response
criteria and RECIST v1.1 in patients with advanced melanoma treated with
Pembrolizumab. J Clin Oncol. 2016;34:1510–7.
116. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl J Med.
2010;363:711–23.
117. Palena C, Hamilton DH. Immune targeting of tumor epithelial-mesenchymal
transition via Brachyury-based vaccines. Adv Cancer Res. 2015;128:69–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jayachandran et al. Journal of Hematology & Oncology  (2016) 9:74 Page 12 of 12
